Expression of interferon receptors in pancreatic cancer: Identification of a novel prognostic factor

Surgery

Volumn 139, Issue 6, 2006, Pages 743-748

  Saidi, Reza F ^a   Williams, Frances ^a   Silberberg, Boris ^a   Mittal, Vijay K ^a   ReMine, Stephen G ^a   Jacobs, Michael J ^a  

^a PROVIDENCE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; SURVIVAL RATE; SURVIVAL TIME; TISSUE SECTION;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTORS, INTERFERON;

EID: 33745149996     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2005.11.010     Document Type: Article

References (21)

1. Jemal A., Tiwari R.C., Murray T., et al. American Cancer Society-Cancer Statistics-2003. CA Cancer J Clin 53 (2003) 5-26
2. Warshaw A.L., and Fernandez-del C.C. Pancreatic carcinoma. N Engl J Med 326 (1992) 455-465
3. Ahrendt S.A., and Pitt H.A. Surgical management of pancreatic cancer. Oncology 16 (2002) 725-734
4. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 67 (1998) 227-264
5. Der S.D., Zhou A., Williams B.R., and Silverman R.H. Identification of genes differentially regulated by interferon β or using oligonucleotide arrays. Proc Natl Acad Sci U S A 95 (1998) 15623-15628
6. de Veer M.J., Holko M., Frevel M., et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukocyte Bio 69 (2001) 912-920
7. Kaplan D.H., Shankaran V., Dighe A.S., et al. Demonstration of an interferon-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95 (1998) 7556-7561
8. Afsari A., Zhou Z., Young S., Ferguson L., Sumet S., and Mittal V. Outcome analysis of pancreaticoduodenectomy at a community hospital. Am Surg 68 (2002) 281-285
9. Jacobs M., Mittal V., ReMine S., and Young S. Defining the role of adjuvant therapy for adenocarcinoma of the pancreas. Curr Surg 61 (2004) 125-130
10. Brembeck F.H., Schoppmeyer K., Leupold U., et al. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer 83 (1998) 2317-2323
11. Moore Jr. D.F., Pazdur R., Sugarman S., et al. Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. Am J Clin Oncol 18 (1995) 525-527
12. Macdonald J.S., Jacobson J.L., Modiano M., et al. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma. a Southwest Oncology Group study (SWOG 9413). Invest New Drugs 18 (2000) 269-273
13. Bernhard H., Jager-Arand E., Bernhard G., et al. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A. results of a phase II trial. Br J Cancer 71 (1995) 102-105
14. Sparano J.A., Lipsitz S., Wadler S., et al. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol 19 (1996) 546-551
15. John W.J., and Flett M.Q. Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma. Am J Clin Oncol 21 (1998) 147-150
16. David A.K., Vaughn D.J., Holroyde C.P., Armstead B., and Haller D.G. A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma. a Penn Cancer Clinical Trials Group (PCCTG) trial. Am J Clin Oncol 23 (2000) 37-39
17. Wagener D.J., Wils J.A., Kok T.C., Planting A., Couvreur M.L., and Baron B. Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer. an EORTC gastrointestinal tract cancer group trial. Eur J Cancer 38 (2002) 648-653
18. Picozzi V.J., Kozarek R.A., and Traverso L.W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185 (2003) 476-480
19. Picozzi V.J., and Traverso L.W. The Virginia Mason approach to localized pancreatic cancer. Surg Oncol Clin N Am 13 (2004) 663-674
20. Available at: http://www.acosog.org/studies/synopses/Z05031_Synopsis.pdf
21. Saidi R.F., Williams F., Ng J., et al. Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. Am J Surg 191 (2006) 358-363